TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07226895: A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

Sponsor: Monument Therapeutics Limited · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 150 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,552,100

Rescue Site Savings

+$1,015,920

Unlock Full NCT07226895 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07226895 Rescue Dossier →